Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ampio Pharmaceuticals Inc Receives FDA Acceptance Of Patient Outcome For Premature Ejaculation (POPE) Questionnaire


Monday, 11 Mar 2013 04:00am EDT 

Ampio Pharmaceuticals Inc announced FDA acceptance of POPE questionnaire, a modification of the Premature Ejaculation Profile (PEP) questionnaire that was used in the two Zertane Phase 3 clinical trials completed in Europe. The completion of this trial and acceptance of the POPE by the FDA allows Ampio (or a pharmaceutical partner) to file an IND in the USA for a pivotal trial of Zertane with POPE as a co-primary end-point along with Intravaginal Ejaculatory Latency Time (IELT). 

Company Quote

6.22
0.25 +4.19%
14 Jun 2013